Secondary Logo

Journal Logo

HOPKINS MICHAEL P. MD; KUMAR, NEELAM B. MD; MORLEY, GEORGE W. MD
Obstetrics & Gynecology: December 1987
ORIGINAL ARTICLE: PDF Only
Free

Sixty-eight patients with epithelial ovarian tumors of low malignant potential treated at the University of Michigan Medical Center were reviewed for clinical and pathologic features related to recurrence or death. The ovarian tumor of low malignant potential represented 12.6% of all ovarian cancers and 22% of all serous or mucinous tumors. Thirty-four patients were stage I (SO%), 13 were stage I1 (19%), 17 were stage 111 (25%), two patients could not be staged, and two patients developed ovarian tumor of low malignant potential in a residual ovary. The risk of recurrence was significantly related to stage 111 disease (P = .023), high nuclear atypia (P = .020), and high grade (P = .017); and was unrelated to capsular status, the presence of psammoma bodies, nucleoli, cribriform pattern, stratification, cystade-nofibroma, tumor size, or spillage at surgery. Therapy in all stages included observation, chemotherapy, or radiotherapy. There was one recurrence in 47 patients with stages 1–11, and 11 recurrences in 17 patients with stage 111 disease. The ovarian tumor of low malignant potential carries an extremely favorable prognosis in stage I and I1 regardless of therapy. Radiotherapy appeared to extend disease-free survival in stage 111 disease, and future randomized studies should consider this treatment modality.

© 1987 The American College of Obstetricians and Gynecologists